Table 1.

Select outcomes of ASCT for relapsed or refractory FL.

	Number of Patients	R included in salvage CT	PFS	OS	Ref
Schouten et al, 2000	65	0	55–58% at 2 year	71–77% at 4 year	24
Rohatiner et al, 2007	121	0	55% at 5 year	71% at 5 years	44
Sebban, et al, 2008	98	33%	51% at 5 year	70% at 5 year	45
Vose, et al, 2008	248	Few (not reported)	44% at 5 year	63% at 5 year	46
Tarella et al, 2008	61+	100%	57 at 5 year	75% at 5 year	25
Le Gouill et al, 2011	112*	100%	52 at 3 year	92% at 3 year	43
Le Gouill et al, 2011	53*	0	40 at 3 year	63% at 3 year	43
Evens et al, 2013	135	100%	57% at 3 year	87% at 3 year	83
Pettengell et al, 2013	280	0	48–42% at 10 years	66.1–74.5% at 10 year	50
Klyuchnikov et al#, 2015	250	100%	41% at 5 year	74% at 5 year	41
Klyuchnikov et al$, 2015	136	100%	36% at 5 year	59 at 5 year	42

⁺considered only R-HDS arm,

^*Considering the trial end point, bot arm (with and without rituximab) are listed,

^#Only Grade 2 FL were included in this study,

^$Only Grade 3 FL were included in this study.